RecruitingPhase 2NCT06418789
High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
- Principal Investigator
- Aleksei M Belyaev, MD,DSc,Prof.National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia
- Intervention
- High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles )(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2024 – 2029
Study locations (1)
- National Medical Research Center of Oncology named after N.N.Petrov Ministry of health of Russia, Saint Petersburg, Russian Federation, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06418789 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology